Pacific Biosciences Of California (PACB) Total Non-Current Liabilities (2010 - 2026)

Pacific Biosciences Of California's Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $772.0 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed 0.37% year-over-year to $772.0 million; the TTM figure through Mar 2026 stood at $772.0 million (changed 0.37% YoY), while the FY2025 annual figure was $778.7 million, up 5.93% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $772.0 million, down from $778.7 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $1.2 billion in Q2 2023, with the low at $735.2 million in Q4 2024.
• The 5-year median for Total Non-Current Liabilities is $1.0 billion (2023), against an average of $966.0 million.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities surged 620.77% in 2022, then dropped 29.58% in 2024.
• Pacific Biosciences Of California's Total Non-Current Liabilities stood at $1.2 billion in 2022, then retreated by 13.21% to $1.0 billion in 2023, then decreased by 29.58% to $735.2 million in 2024, then increased by 5.93% to $778.7 million in 2025, then declined by 0.86% to $772.0 million in 2026.
• Business Quant data shows PACB's Total Non-Current Liabilities at $772.0 million in Q1 2026, $778.7 million in Q4 2025, and $767.1 million in Q3 2025.